Aegerion Pharmaceuticals said Monday that it has won Food and Drug Administration approval to sell its first drug, a treatment for a rare inherited genetic disorder that can raise cholesterol to life-threatening levels.

The condition, homozygous familial hypercholesterolemia, or HoFH, is resistant to statins and other medications typically used to bring high cholesterol under ­control.